

**KURZPROTOKOLL**  
**ADAPT-TN-III**

|                                                  |                                                                                                                                                                                                                                 |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Öffentlicher Titel</b>                        | NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer                                          |
| <b>Wissenschaftl. Titel</b>                      | NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer                                          |
| <b>Kurztitel</b>                                 | ADAPT-TN-III                                                                                                                                                                                                                    |
| <b>Studienart</b>                                | Therapiestudie                                                                                                                                                                                                                  |
| <b>Studienphase</b>                              | Phase II                                                                                                                                                                                                                        |
| <b>Erkrankung</b>                                | Geschlechtsorgane: Brustkrebs: neoadjuvant                                                                                                                                                                                      |
| <b>Alter</b>                                     | 18 Jahre und älter                                                                                                                                                                                                              |
| <b>Molekularer Marker</b>                        | HER2/neu neg.<br>ER/PR neg.                                                                                                                                                                                                     |
| <b>Prüfzentren</b>                               | <b>Agaplesion Markus Krankenhaus</b><br>Wilhelm-Epstein-Straße 4<br>60431 Frankfurt am Main<br>PD Dr. med. Marc Thill<br>Tel: 069 95332228<br>Fax: 069 95332733<br><a href="mailto:marc.thill@fdk.info">marc.thill@fdk.info</a> |
| <b>Sponsor</b>                                   | West German Study Group                                                                                                                                                                                                         |
| <b>Registrierung in anderen Studienregistern</b> | EUCT 2023-508787-29-00                                                                                                                                                                                                          |
| <b>Links</b>                                     | <a href="#">Ein- und Ausschlusskriterien</a>                                                                                                                                                                                    |